Besides ABL in CML, Ponatinib strongly inhibits other kinases such as FGFR, FLT3, KIT, and PDFGRα (Supplementary Fig. 3)34–36 and it was previously reported in kinome screens to inhibit BRAF activity, however, it is not validated or recognized as BRAF inhibitor13,37. This evidence concerns the gene FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive.